Novartis has boosted its 2024 outlook for a second time this year, thanks to strong sales for some of its biggest drugs used to treat heart failure and other ailments.
Novartis lifts guidance again as demand climbs for top drugs
Read Next
- BitMEX Schedules System Maintenance, Platform to Face Temporary Downtime
- India to clock 7.2 pc growth in 2024, RBI to hold interest rates steady this year: Moody’s, ET BFSI
- HKEX partners with Hang Seng Indexes Company to launch Hang Seng HKEX Stock Connect China Enterprises Index
- Mormugao port in World Bank’s green spotlight, BFSI News, ET BFSI
- Trump picking Matt Gaetz for AG puts House sex, drug probe in focus
- 7 habits of people who always seem to get lucky in life, according to psychology
- BitMEX to List SWELLUSDT and APUUSDT Perpetual Swaps with 50x Leverage
